Last week it was announced that the German firm TVM Capital will manage a Montréal fund dedicated to the life sciences sector and meant to allow the multinational pharmaceutical Eli Lilly, amongst others, to set up shop in Québec’s metropolis.
With $150M planned investments, does this mean that Québec’s industrial policy regarding biotech has suddenly been brought back to life? No, actually, it doesn’t.
On the contrary, the time has come to assess how effective policies regarding the pharmaceutical industry are. For some twenty years, Québec has put everything in place to attract giants of this powerful industry. The aim was obviously to take advantage of the spillovers regarding investments, research, employment, etc.
1 Comment
